Top of this page
Skip navigation, go straight to the content
At UCB,
we aspire to be the patient-preferred biotech leader.
To achieve this goal, UCB has become an innovation-driven global biopharmaceutical company creating value for patients, the company, its shareholders and society in general.
Our work has an impact on the lives of many people. Every UCB employee is committed to follow the strict regulatory standards for research, development, manufacturing and distribution of our products to ensure we meet all safety, quality, regulatory, legal and environmental requirements.
In an ever-changing and more complex environment, UCB’s patient value strategy is the best route to achieve this ambition and long-term success.
Agreement to acquire
Ra Pharma
IR events
| Date | Event details |
|---|---|
| 07 November 2019 | Roadshow in Munich (non deal roadshow)If you are interested, please contact us. |
| 12 November 2019 | Société Générale - European ESG & SRI Conference, Paris1/1 meetings |
| 20 November 2019 | Jefferies 2019 Healthcare Conference, London1/1 meetings |
Latest News
-
18 Oct 2019
Transparency notification Vanguard Health Care Fund
- 18 Oct 2019 EVENITY® (romosozumab) Receives Positive CHMP Opinion for the Treatment of Severe Osteoporosis in Postmenopausal Women at High Risk of Fracture
- 17 Oct 2019 Bimekizumab Phase 3 Psoriasis Study Meets All Endpoints, Achieving Significantly Greater Efficacy Versus Placebo and Ustekinumab
2018 integrated report
2019 HY results
Upcoming report›
| Date | Event details |
|---|---|
| 20 February 2020 | 2019 full year results 07.00 Press release 14.00 Conference call /webcast Exact timing to be confirmed closer to the time |
Outlook 2019 confirmed
The acquisition of Ra Pharma will not impact UCB’s 2019 financial guidance. The acquisition would be dilutive to UCB’s mid-term earnings level due to additional planned R&D investments. As a result, the mid-term target of UCB reaching a REBITDA ratio (to revenue) of 31% would move to 2022 from 2021 as previously guided.
2019 revenue reporting to reach approximately
€ 4.6-4.7 billion
Recurring EBITDA [Operating profit adjusted for amortisation, depreciation, impairment charges, restructuring expenses and other exceptional income and expenses.] in the range of
27-29% of revenue
Core earnings per share are therefore expected in the range of
€ 4.40-4.80
based on an average of
188 million shares outstanding
Contact UCB IR team
investor-relations@ucb.com or a specific team member:
- Antje Witte, VP Investor Relations
Tel: +32 2 559 9414
E-mail: Antje.Witte@ucb.com - Isabelle Ghellynck, Associate Director Investor Relations
Tel: +32 2 559 9588
E-mail: Isabelle.Ghellynck@ucb.com - Nathalie Deldime, Investor Relations Events Manager
Tel: +32 2 559 9291
E-mail: Nathalie.Deldime@ucb.com
UCB IR App
